ACUTAAS Acutaas Chemicals Q2 FY27 results (Jul–Sep 2026) and concall
Acutaas Chemicals Limited delivered exceptional operating results in Q2 FY27, with revenue growing 42.7% YoY to Rs. 4,369 million and EBITDA margins expanding by 914 bps YoY to 40.3%. Strong momentum in the Advanced Pharmaceutical Intermediate division (+53.1% YoY) enabled management to advance its Rs. 1,000 crore CDMO milestone to FY27, alongside a new target to double CDMO revenues to Rs. 2,000 crores by FY30. Consequently, management raised its FY27 revenue growth guidance to ~30% and EBITDA margin guidance to 38%-40%. The company commenced commercial sales in battery chemicals and inaugura
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 42.8%, net profit up 70.8% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 275 | 308 | 207 | 306 | 393 +43% | 433 +41% | 330 +59% | 437 +43% |
| EBITDA | 69 | 85 | 51 | 95 | 151 +119% | 184 +116% | 113 +122% | 176 +85% |
| Net profit | 45 | 63 | 44 | 72 | 106 +136% | 134 +113% | 75 +70% | 123 +71% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
